MedTrace Logo

Investigate the Effect of AZD1656 on the Pharmacokinetics of Sitagliptin in Patients With Type 2 Diabetes Mellitus

NCT01095991 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2010-07-01

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effects of AZD1656 on Sitagliptin pharmacokinetics and vice versa in patients with Type 2 Diabetes Mellitus.

Conditions

Interventions

DRUG

AZD1656

Oral tablet bd,

DRUG

Sitagliptin

Oral tablet od

Sponsors & Collaborators

Principal Investigators

  • Stanko Skrtic · AstraZeneca Molndal Sweden

  • Christoph Kapitza · Profil Institut für Stoffwechselforschung GmbH

  • Mirjana Kujacic · AstraZeneca Molndal Sweden

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2010-05-31
Completion
2010-05-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01095991 on ClinicalTrials.gov